Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Becker's Hospital Review9h
AI helps Cleveland Clinic uncover new uses for existing drugs
Cleveland Clinic researchers are using artificial intelligence to identify existing FDA-approved drugs that may be repurposed to treat other complex diseases. The effort is led by Feixiong Cheng, PhD, ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Medscape23h
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Interesting Engineering on MSN6h
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
TipRanks on MSN22h
Bonus Biogroup Gains FDA Approval for Crucial Phase III ARDS Drug Trial
Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID ...
Medtronic reports third quarter fiscal 2025 financial results
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.